x

Posted 10 June, 2021

Syros Pharmaceuticals, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:SYRS in a 8-K filed on 10 June, 2021.


  On June 8, 2021, the Board of Directors (the "Board") of the Company appointed Nancy Simonian, M.D., the Company's President and Chief Executive Officer, as the Company's interim principal financial officer and principal accounting officer effective June 16, 2021.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Syros Pharmaceuticals, Inc.
Health Care/Life Sciences • Biotechnology
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Market Cap
$198M
View Company Details
Syros Pharmaceuticals, Inc. by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. 


(b) 

On June 7, 2021, Joseph J. Ferra, Jr., notified Syros Pharmaceuticals, Inc. (the "Company") of his decision to resign from his position as Chief Financial Officer (and principal financial and accounting officer), effective June 15, 2021. Mr. Ferra's resignation is not a result of any disagreement with the Company's independent auditors or any member of management on any matter of accounting principles or practices, financial statement disclosure or internal controls. Mr. Ferra will remain at the Company as a consultant through July 23, 2021 in order to support the transition of his responsibilities. The Company is currently engaged in a search process for a new Chief Financial Officer. 

(c) 

On June 8, 2021, the Board of Directors (the "Board") of the Company appointed Nancy Simonian, M.D., the Company's President and Chief Executive Officer, as the Company's interim principal financial officer and principal accounting officer effective June 16, 2021. Biographical information for Dr. Simonian is available in the Company's proxy statement filed with the Securities and Exchange Commission on April 29, 2021 in connection with the Company's 2021 annual meeting of stockholders, such information being incorporated herein by reference.